Drugs / Peginterferon Alfa-2a (40KD)
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00460850 | Sep 2007 → Jun 2008 | chronic hepatitis B virus infection | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 4 | NCT00707850 | May 2007 → Sep 2009 | chronic hepatitis C virus infection, thalassemia | Baqiyatallah Medical Sciences University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00707772 Comparator | Mar 2007 → Sep 2009 | chronic hepatitis C virus infection, hemophilia | Baqiyatallah Medical Sciences University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon Alfa-2a (40KD) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00707850 ↗ |
| Known as | PEGASYS | “PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)” NCT00707772 ↗2“PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)” NCT00707850 ↗ “peginterferon alfa-2a (40KD) [PEGASYS]” NCT00460850 ↗ |
| Route | Subcutaneous | “180 micrograms sc weekly for 48 weeks” NCT00460850 ↗ |